Data Bridge Market Research analyzes that the Asia-Pacific hepatitis B infection market is expected to reach USD 6.52 billion by 2031 from USD 4.03 billion in 2023, growing with a CAGR of 6.2% in the forecast period of 2024 to 2031.
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC HEPATITIS B INFECTION MARKET
1.4 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 THERAPEUTICS LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTAL ANALYSIS
4.2 PORTER FIVE FORCES
5 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: REGULATIONS
5.1 REGULATORY AUTHORITIES IN THE ASIA-PACIFIC REGION
5.2 NORTH AMERICA REGULATORY SCENARIO
5.3 EUROPE REGULATORY SCENARIO
5.4 MIDDLE EAST AND AFRICA REGULATORY SCENARIO
5.5 SOUTH AMERICA REGULATORY SCENARIO
6 PIPELINE ANALYSIS
7 EPIDEMILIOGY
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASING PREVALENCE OF HEPATITIS B INFECTIONS
8.1.2 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTICS
8.1.3 DEVELOPMENT OF COMBINATION THERAPIES FOR HEPATITIS B
8.1.4 STRATEGIC INITIATIVES BY COMPANIES FOR HEPATITIS B INFECTION
8.2 RESTRAINTS
8.2.1 SIDE EFFECTS AND DRUG RESISTANCE
8.2.2 INSUFFICIENT VACCINE COVERAGE FOR HEPATITIS B INFECTION
8.3 OPPORTUNITY
8.3.1 RISING NEW DRUG RELEASES AND INCREASING NEW DRUG PERMITS FOR HEPATITIS B
8.3.2 GOVERNMENT PROGRAMS TO RAISE AWARENESS OF HEPATITIS B INFECTION
8.3.3 ADVANCED RESEARCH AND DEVELOPMENT FOR CLINICAL TRIALS
8.4 CHALLENGES
8.4.1 THE COST OF HEPATITIS B TREATMENTS IS HIGH
8.4.2 STRINGENT REGULATORY POLICIES AND REGIONAL DISPARITIES IN TREATMENT ACCESS
9 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TYPE
9.1 OVERVIEW
9.2 CHRONIC
9.3 ACUTE
10 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 VACCINE
10.2.1 HOSPITAL PHARMACIES
10.2.2 DRUGS STORES AND RETAIL PHARMACIES
10.2.3 ONLINE PHARMACIES
10.3 ANTIVIRAL DRUGS
10.3.1 TENOFOVIR ALAFENAMIDE FUMARATE (TAF)
10.3.2 TENOFOVIR DISOPROXIL FUMARATE (TDF)
10.3.3 ENTECAVIR
10.3.4 OTHERS
10.4 IMMUNE MODULATOR DRUGS
10.4.1 PEGYLATED INTERFERON
10.4.2 INTERFERON ALPHA
10.5 SURGERY
11 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY REGION
11.1 ASIA-PACIFIC
11.1.1 CHINA
11.1.2 INDIA
11.1.3 INDONESIA
11.1.4 JAPAN
11.1.5 VIETNAM
11.1.6 PHILIPPINES
11.1.7 THAILAND
11.1.8 SOUTH KOREA
11.1.9 AUSTRALIA
11.1.10 SINGAPORE
11.1.11 MALAYSIA
11.1.12 NEW ZEALAND
11.1.13 TAIWAN
11.1.14 REST OF ASIA-PACIFIC
12 ASIA-PACIFIC HEPATITIS B TREATMENT MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 GILEAD SCIENCES, INC.
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 GLAXOSMITHKLINE PLC
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENT
14.3 DYNAVAX TECHNOLOGIES CORPORATION
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENTS
14.4 F. HOFFMAN-LA ROCHE LTD.
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 BRISTOL-MYERS SQUIBB COMPANY
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENTS
14.6 ARROWHEAD PHARMACEUTICALS, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.7 ARBUTUS BIOPHARMA
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT UPDATES
14.8 AUROBINDO PHARMA
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT UPDATES
14.9 LUPIN PHARMACEUTICALS, INC.
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT UPDATES
14.1 MERCK & CO., INC.,
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENTS
14.11 NOVARTIS AG
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 TEVA PHARMACEUTICAL INDUSTRIES
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 ZYDUS PHARMACEUTICALS, INC.
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 REVENUE
14.13.4 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
List of Table
TABLE 1 ASIA-PACIFIC CLINICAL TRIAL AND PIPELINE A-LYSIS AS PER THE COMPANY
TABLE 2 DISTRIBUTION OF PRODUCTS OR PROJECTS BY PHASE
TABLE 3 COUNTRY WISE EPIDEMIOLOGY FOR HEPATITIS B
TABLE 4 COST OF HEPATITIS B MEDICATIONS: BRAND VS. GENERIC PRICES
TABLE 5 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 6 ASIA-PACIFIC CHRONIC IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 7 ASIA-PACIFIC ACUTE IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 8 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 9 ASIA-PACIFIC VACCINE IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 10 ASIA-PACIFIC VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 11 ASIA-PACIFIC ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 12 ASIA-PACIFIC ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 13 ASIA-PACIFIC IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 14 ASIA-PACIFIC IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 15 ASIA-PACIFIC SURGERY IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 16 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 17 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 18 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 19 ASIA-PACIFIC ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 20 ASIA-PACIFIC IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 21 CHINA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 22 CHINA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 23 CHINA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 24 CHINA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 25 CHINA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 26 CHINA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 27 INDIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 28 INDIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 29 INDIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 30 INDIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 31 INDIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 32 INDONESIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 33 INDONESIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 34 INDONESIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 35 INDONESIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 36 INDONESIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 37 JAPAN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 38 JAPAN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 39 JAPAN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 40 JAPAN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 41 JAPAN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 42 VIETNAM HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 43 VIETNAM HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 44 VIETNAM ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 45 VIETNAM IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 46 VIETNAM VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 47 PHILIPPINES HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 48 PHILIPPINES HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 49 PHILIPPINES ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 50 PHILIPPINES IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 51 PHILIPPINES VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 52 THAILAND HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 53 THAILAND HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 54 THAILAND ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 55 THAILAND IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 56 THAILAND VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 57 SOUTH KOREA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 58 SOUTH KOREA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 59 SOUTH KOREA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 60 SOUTH KOREA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 61 SOUTH KOREA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 62 AUSTRALIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 63 AUSTRALIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 64 AUSTRALIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 65 AUSTRALIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 66 AUSTRALIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 67 SINGAPORE HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 68 SINGAPORE HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 69 SINGAPORE ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 70 SINGAPORE IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 71 SINGAPORE VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 72 MALAYSIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 73 MALAYSIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 74 MALAYSIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 75 MALAYSIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 76 MALAYSIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 77 NEW ZEALAND HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 78 NEW ZEALAND HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 79 NEW ZEALAND ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 80 NEW ZEALAND IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 81 NEW ZEALAND VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 82 TAIWAN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 83 TAIWAN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 84 TAIWAN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 85 TAIWAN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 86 TAIWAN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 87 REST OF ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
List of Figure
FIGURE 1 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: SEGMENTATION
FIGURE 11 TWO SEGMENTS COMPRISE THE ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TYPE
FIGURE 12 EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 ASIA-PACIFIC HEPATITIS B INFECTION MARKET
FIGURE 15 CHRONIC SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC HEPATITIS B INFECTION MARKET IN 2024 & 2031
FIGURE 16 DROC ANALYSIS
FIGURE 17 BURDEN OF HBV INFECTION IN THE GENERAL POPULATION BY WHO REGION, 2019
FIGURE 18 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: BY TYPE, 2023
FIGURE 19 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: BY TYPE, 2024-2031 (USD MILLION)
FIGURE 20 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 21 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: BY TREATMENT, 2023
FIGURE 23 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: BY TREATMENT, 2024-2031 (USD MILLION)
FIGURE 24 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 25 ASIA-PACIFIC HEPATITIS B INFECTION MARKET BY TREATMENT, LIFELINE CURVE
FIGURE 26 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, SNAPSHOT
FIGURE 27 ASIA-PACIFIC HEPATITIS B TREATMENT MARKET: COMPANY SHARE 2023 (%)
